摘要
Psoriasis is a chronic inflammatory immune-mediated skin diseases which is frequently associated to comorbidities. Non-alcoholic fatty liver disease(NAFLD) is defined as an excessive accumulation of triglycerides in hepatocytes and includes a wide spectrum of liver conditions ranging from relatively benign steatosis to non-alcoholic steatohepatitis with fatty infiltration and lobular inflammation and to cirrhosis and endstage liver disease. Actually, psoriasis is considered a systemic diseases associated to comorbidities, as metabolic syndrome and NAFLD is seen the hepatic manifestation of the metabolic syndrome. The possible link between psoriasis, obesity and metabolic syndrome, which are known risk factors for NAFLD has beenrecently documented focusing in the crucial role of the adipose tissue in the development of the inflammatory background sharing by the above entities. According to recent data, patients with psoriasis show a greater prevalence of NAFLD and metabolic syndrome than the general population. Moreover, patients with NAFLD and psoriasis are at higher risk of severe liver fibrosis than those with NAFLD and without psoriasis. The link between these pathological conditions appears to be a chronic low-grade inflammatory status. The aim of this review is to focus on the multiple aspects linking NAFLD and psoriasis, only apparently far diseases.
Psoriasis is a chronic inflammatory immune-mediatedskin diseases which is frequently associated tocomorbidities. Non-alcoholic fatty liver disease （NAFLD）is defined as an excessive accumulation of triglyceridesin hepatocytes and includes a wide spectrum of liverconditions ranging from relatively benign steatosisto non-alcoholic steatohepatitis with fatty infiltrationand lobular inflammation and to cirrhosis and endstageliver disease. Actually, psoriasis is considereda systemic diseases associated to comorbidities, asmetabolic syndrome and NAFLD is seen the hepaticmanifestation of the metabolic syndrome. The possiblelink between psoriasis, obesity and metabolic syndrome,which are known risk factors for NAFLD has beenrecently documented focusing in the crucial role of theadipose tissue in the development of the inflammatorybackground sharing by the above entities. Accordingto recent data, patients with psoriasis show a greaterprevalence of NAFLD and metabolic syndrome thanthe general population. Moreover, patients with NAFLDand psoriasis are at higher risk of severe liver fibrosisthan those with NAFLD and without psoriasis. The linkbetween these pathological conditions appears to be achronic low-grade inflammatory status. The aim of thisreview is to focus on the multiple aspects linking NAFLDand psoriasis, only apparently far diseases.
